Eradikate Salicylic Acid Acne Treatment
Salicylic Acid
Kate Somerville Skincare, Llc
Human Otc Drug
NDC 43479-111Eradikate Salicylic Acid Acne Treatment also known as Salicylic Acid is a human otc drug labeled by 'Kate Somerville Skincare, Llc'. National Drug Code (NDC) number for Eradikate Salicylic Acid Acne Treatment is 43479-111. This drug is available in dosage form of Lotion. The names of the active, medicinal ingredients in Eradikate Salicylic Acid Acne Treatment drug includes Salicylic Acid - 2 g/100mL . The currest status of Eradikate Salicylic Acid Acne Treatment drug is Active.
Drug Information:
| Drug NDC: | 43479-111 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Eradikate Salicylic Acid Acne Treatment |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Salicylic Acid |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Kate Somerville Skincare, Llc |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Lotion |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | SALICYLIC ACID - 2 g/100mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 18 Nov, 2018 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 09 May, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part333D |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | KATE SOMERVILLE SKINCARE, LLC
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 103568
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | O414PZ4LPZ
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 43479-111-51 | 1 BOTTLE in 1 BOX (43479-111-51) / 30 mL in 1 BOTTLE (43479-111-11) | 18 Nov, 2018 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose acne medication
Product Elements:
Eradikate salicylic acid acne treatment salicylic acid water glycereth-7 trimethyl ether cetyl alcohol medium-chain triglycerides isopropyl isostearate trimethylolpropane tricaprylate/tricaprate steareth-21 dimethicone glycereth-18 ethylhexanoate propanediol steareth-2 retinyl propionate hexylresorcinol oligopeptide-10 proline hydroxyproline ethyl linoleate hyaluronate sodium saccharide isomerate sodium pyrrolidone carboxylate panthenol melaleuca alternifolia leaf laminaria digitata boswellia serrata whole honey rice bran chlorella vulgaris glycerin butylene glycol glycereth-18 trimethylpentanediol/adipic acid/glycerin crosspolymer (25000 mpa.s) 1,2-hexanediol ammonium acryloyldimethyltaurate, dimethylacrylamide, lauryl methacrylate and laureth-4 methacrylate copolymer, trimethylolpropane triacrylate crosslinked (45000 mpa.s) polymethylsilsesquioxane (4.5 microns) aminomethylpropanol caprylhydroxamic acid edetate disodium phenoxyethanol sodium benzoate ethylhexylglycerin lavender oil disodium carboxyethyl siliconate tert-butyl alcohol linalool, (+)- limonene, (+)- ferric oxide red salicylic acid salicylic acid
Indications and Usage:
Uses for the treatment of acne helps keep skin clear of new acne blemishes
Warnings:
Warnings for external use only
When Using:
When using this product using other topical acne medication at the same time or immediately following the use of this product may increase dryness or irritation of the skin. if this occurs, only one medication should be used unless directed by a doctor. avoid contact with eyes. if excessive skin irritation develops or increases, discontinue use and consult a doctor.
Dosage and Administration:
Use 1 to 2 times weekly gently apply an even layer to clean, wet skin using circular motions leave on for 1 minute gently wash off and pat dry.
Stop Use:
Stop use and ask a doctor if skin irritation occurs.
Package Label Principal Display Panel:
0-image_eradikate salicylic acid treatment_1oz